DrugPatentWatch Database Preview

ZOSYN Drug Profile

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

When do Zosyn patents expire, and when can generic versions of Zosyn launch?

Zosyn is a drug marketed by Wyeth Pharms and is included in two NDAs. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has forty-one patent family members in thirty-four countries.

The generic ingredient in ZOSYN is piperacillin sodium; tazobactam sodium. There are sixteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the piperacillin sodium; tazobactam sodium profile page.

US ANDA Litigation and Generic Entry Outlook for Zosyn

There are two Paragraph IV patent challenges for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for ZOSYN

International Patents:	41
US Patents:	3
Applicants:	1
NDAs:	2
Suppliers / Packagers:	1
Bulk Api Vendors:	69
Patent Applications:	2,223
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for ZOSYN
DailyMed Link:	ZOSYN at DailyMed

See drug prices for ZOSYN

Pharmacology for ZOSYN

Drug Class	beta Lactamase Inhibitor Penicillin-class Antibacterial
Mechanism of Action	beta Lactamase Inhibitors

Synonyms for ZOSYN

(2S,3S,5R)-3-((1H-1,2,3-triazol-1-yl)methyl)-3-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide

(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(1-triazolylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4$l;{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4

(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4?^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-[(1H-1,2,3-triazol-1-yl)methyl]-4lambda(6)-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

(2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid

(2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda 6-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid

(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda6-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid

(2S,3S,5R)-3-methyl-4,4,7-tris(oxidanylidene)-3-(1,2,3-triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

(2S,3S,5R)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide

(2S,3S,5R)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 4,4-dioxide

(2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide

(2S,3S,5S)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide

3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-1-ylmethyl-4lambda*6*-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid

4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2S-(2alpha,3beta,5alpha))-

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-methyl-7- oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, [2S- (2alpha,3beta,5alpha)]-

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2S,3S,5R)-

786T049

89786-04-9

89786-04-9, 89785-84-2 (sodium salt)

A-8312

A843310

AC-7620

AC1L3X07

AJ-45613

AK163672

AKOS015960801

AN-8836

API0004329

AX8040438

BC204218

BCP09757

BDBM50053173

BIDD:GT0212

BRD-K14312455-001-01-6

BRN 4787943

C-18753

C07771

CC-34652

CCG-207890

CCRIS 2203

CHEBI:9421

CHEMBL404

CL 298,741

Cl 298741

CL-298741

CL298741

CS-4914

D00660

DB01606

DS-8301

DTXSID8023634

EC 618-303-7

EX-A1377

FT-0630968

HMS3714G17

HY-B1418

KS-00000KZ3

LPQZKKCYTLCDGQ-WEDXCCLWSA-N

MolPort-002-500-123

s3077

SC-15957

SCHEMBL122302

SE10G96M8W

SR-01000872598

SR-01000872598-1

SR-01000872598-2

ST24049330

T-1445

Tazobactam

Tazobactam (JP17/USAN/INN)

Tazobactam [USAN:USP:INN:BAN]

Tazobactam acid

Tazobactam, Antibiotic for Culture Media Use Only

Tazobactam,(S)

Tazobactam;Tazobactan acid

Tazobactamum

Tazobactamum [INN-Latin]

Tazobactum (Free acid)

UNII-SE10G96M8W

YTR 830 H

YTR 830H

YTR-830H

YTR830

YTR830H

ZINC3787060

Paragraph IV (Patent) Challenges for ZOSYN

Tradename	Dosage	Ingredient	NDA	Submissiondate
ZOSYN	INJECTABLE;INJECTION	piperacillin sodium; tazobactam sodium	050684	2011-12-06

US Patents and Regulatory Information for ZOSYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms	ZOSYN	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050684-001	Oct 22, 1993	AP	RX	Yes	Yes			Y
Wyeth Pharms	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-001	Feb 24, 1998		RX	Yes	Yes			Y
Wyeth Pharms	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-002	Feb 24, 1998		RX	Yes	Yes			Y

International Patents for ZOSYN

Country	Patent Number	Estimated Expiration
Costa Rica	8035
Saudi Arabia	1990
Denmark	1468697